Luoxin pharmaceutical: delayed disclosure of the first quarter report of 2022
Luoxin pharmaceutical announced that affected by the epidemic situation of novel coronavirus pneumonia, some regions implemented epidemic prevention and control measures, which affected the progress of the company's preparation of the first quarter report of 2022. Now, the first quarter report of 2022 is postponed to be disclosed on April 30, 2022.
This text is a result of machine translation.
Related companies：
In-depth
Communication
Forty Years of Striving: How Globalization Has Shaped Lenovo Today?
The year 2024 marks the 40th anniversary of Lenovo’s founding and the 20th year of its globalization journey. On October 30, Lenovo Group co-hosted the “Pioneers’ Voyage: 2024 Chinese Enterprises’ High-Quality Global Expansion Forum” with Sina Finance, Citic Publishing Group, and the think tank of Tsinghua University’s School of Economics and Management at the Zhongguancun International Innovation Center in Beijing.
Nov 07, 2024 06:51 PM
Briefing May 23, 2022 12:38 PM
· Healthcare
Aimeike signs distribution cooperation framework agreement with South Korea huons BP
Briefing Feb 25, 2022 09:58 AM
· Healthcare
The steel sector strengthened significantly
Dec 11, 2023 08:49 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Briefing Dec 09, 2021 10:39 AM
Baijiu plate strength, mouth cellar line exceeds 10%
Briefing Oct 22, 2021 10:13 PM
· Real Estate
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
Briefing Oct 19, 2021 06:56 AM
· Financials
The investment banking business was strictly supervised, and seven securities companies received fines
Briefing Oct 17, 2021 06:26 PM
· Healthcare
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
Briefing Sep 24, 2021 11:28 AM
· Healthcare
The medical and American plate rose sharply
Briefing Aug 23, 2021 07:46 PM
· Healthcare
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
Communication · Analysis
Exclusive Interview with Dynabridge Founder Yao Yao
"Every Category is Worth Revisiting with a Branding Approach." Against the backdrop of a rapidly restructured global manufacturing landscape, Chinese companies face a crucial choice: continue competing in low-profit OEM models or invest in building globally influential, independent brands?
Nov 15, 2024 09:44 AM
Briefing Jul 08, 2021 07:41 PM
· Financials
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation
See more
Read next
Insight
In-depth
Consumer Discretionary · Analysis
Black Friday Kicks Off: How to Navigate the Latin American Market?
Nov 20, 2024 10:36 AM
Insight
In-depth
Consumer Staples, Consumer Discretionary · Interview
Exploring Uncharted Territories in the Middle East: The Innovators Going Global
Nov 19, 2024 03:20 PM
Insight
In-depth
Insight
In-depth
Consumer Staples
The Billion-Dollar European Caviar Business, Now Disrupted by China
Nov 08, 2024 01:52 PM